Consultants for Clinical Research, Inc.

Cincinnati, Ohio 95219

0 studies enrolling now · 26 studies all time

What they study most

Colitis, Ulcerative, Crohn Disease, Crohn's Disease, Crohn´s Disease, Eosinophilic Esophagitis (EoE), Gastroesophageal Reflux Disease (GERD), Inflammatory Bowel Disease, Ulcerative Colitis

Studies at this site

• An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) — Completed
• A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved — Completed
• Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 — Stopped early
• A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) — Completed
• A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease — Completed
• Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307) — Stopped early
• An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis — Completed
• A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) — Stopped early
• A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC) — Completed
• Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis — Stopped early
• Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305) — Stopped early
• An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis — Completed
• New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis — Completed
• Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission — Completed
• Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease — Stopped early
• Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study — Completed
• A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease — Withdrawn before enrolling
• Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo — Completed
• A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease — Completed
• A Study of Abatacept in Patients With Active Ulcerative Colitis — Completed
• Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease — Completed
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease — Completed
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis — Completed
• A Study With Pentasa in Patients With Active Crohn's Disease — Stopped early
• CP-461 for the Treatment of Crohn's Disease — Completed